1. Introduction {#sec1}
===============

Hantavirus Pulmonary Syndrome (HPS) is a hallmark capillary leak syndrome with a \~40% mortality rate, and Sin Nombre (SNV) is a prototypical HPS causing hantavirus associated with outbreaks of HPS disease in the Southwestern United States \[[@B1]--[@B5]\]. HPS is characterized by an acute febrile prodrome with thrombocytopenia rapidly progressing to acute pulmonary edema, hypoxia respiratory insufficiency, hypotension, and cardiogenic shock \[[@B1], [@B2], [@B5]--[@B7]\]. Hantaviruses predominantly infect the endothelial cell lining of vessels that form the primary fluid barrier of the vasculature. The pathogenesis of HPS is likely to result from the direct infection of pulmonary endothelial cells as well as hantavirus-induced responses of endothelial and immune cells. Immune cells are hypothesized to contribute to hantavirus disease through elevated levels of CD8^+^ T cells and cytokines such as TNF, yet the vascular endothelium is not disrupted in patients \[[@B5], [@B8]--[@B15]\]. *In vitro* SNV-infected endothelial cells are not permeabilized by infection alone or following the addition of TNF \[[@B14], [@B16]\], however pathogenic hantaviruses bind and inactivate *β*3 integrins which normally restrict VEGF-directed capillary permeability \[[@B17]--[@B21]\]. This nonlytic induction of vascular permeability suggests that hantaviruses alter normal responses of the endothelium to factors that elicit an edematous disease process \[[@B5]--[@B7], [@B10], [@B14], [@B16]--[@B18], [@B22]--[@B26]\].

A suggested role for VEGF in HPS was indicated by the VEGF enhanced permeability of capillaries within *β*3 integrin knockout mice \[[@B21], [@B27], [@B28]\] and findings that pathogenic hantaviruses similarly inhibit *β* ~3~ integrin functions \[[@B17]--[@B19], [@B29]\]. Subsequent analysis demonstrated that hantavirus-infected endothelial cells are hyperresponsive to the permeabilizing effects of VEGF \[[@B18], [@B24], [@B30], [@B31]\]. VEGF is a cytokine that was first identified as a vascular permeability factor for its ability to potently induce edema \~50,000 times more effectively than histamine \[[@B32]\]. VEGF is induced by hypoxic conditions and causes high altitude pulmonary edema (HAPE) by binding to unique endothelial cell receptors that disrupt adherens junctions \[[@B33]--[@B39]\]. VEGF also transcriptionally induces hypoxia inducible factor-1*α* (HIF-1*α*) forming an autocrine loop that exacerbates permeability responses during hypoxia \[[@B36], [@B38]--[@B40]\]. The VEGF sensitivity of SNV infected endothelial cells, the role of VEGF in HAPE, and findings that HPS patients are acutely hypoxic prompted us to retrospectively evaluate VEGF levels in HPS patient samples.

2. Materials and Methods {#sec2}
========================

2.1. HPS Patients {#sec2.1}
-----------------

For this study 31 HPS patients between the ages of 18 and 59 years were referred by their physicians to the University of New Mexico Health Science Center between 1995 and 2001 for treatment of suspected hantavirus infection. Written informed consent was obtained according to guidelines on human experimentation of the U.S. DHHS, and the study was approved by the Human Research Review Committee of the University of New Mexico. Clinical diagnosis was provisionally made by peripheral smear criteria \[[@B1]\] and confirmed by *N*-protein immunoblot assay \[[@B41]\]. As previously described \[[@B42]\], severe disease (*N* = 20) was defined as a requirement for mechanical ventilation (ratio of partial pressure of arterial oxygen/fraction of inspired oxygen \<100). Moderately severe disease (*N* = 2) was defined as the need for inspired oxygen via continuous positive airway pressure (CPAP). Mild disease (*N* = 9) was defined by the need for oxygen delivered by nasal prongs only or no need for oxygen administration. Eight subjects with severe disease developed noncardiogenic shock unrelieved by intravenous vasopressor therapy and were treated with extracorporeal membrane oxygenation (ECMO) \[[@B43]\].

2.2. HPS Patient Samples {#sec2.2}
------------------------

Venous blood was collected in EDTA tubes, centrifuged to separate plasma within one hour of collection, and stored at −80°C until analysis. Peripheral blood mononuclear cells (PBMC) were separated from arterial blood on Ficoll-Hypaque cushions, washed twice in PBS, and cryopreserved in 20% fetal calf serum, 10% DMSO at −70°C. Pulmonary edema fluid (PEF) was collected aseptically by deep aspiration from endotracheal tubes, centrifuged to remove cellular debris, and stored at −80°C. Pulmonary edema fluid (PEF) samples (*N* = 25) were collected from three patients, EDTA plasma samples (*N* = 56) were received from 31 cases, peripheral blood mononuclear cell samples (PBMCs) (*N* = 30) were collected from the blood of 21 patients and 7 serum samples were received from 4 patients. PBMCs were archived at 1.0--2.0 × 10^7^ cells/mL at −80°C and lysed completely after a secondary frosting-defrosting procedure. The lysates did not contain whole PBMC cells and the cells could not be counted prior to assay \[[@B1]\]. VEGF levels are reported as pg/10^7^ cells. Control samples used were derived from 13 plasma and sera samples collected from healthy individuals. Plasma VEGF levels were used as internal controls for PEF samples and control PBMC samples were collected from 6 healthy persons. All samples were coded and assayed without knowledge of clinical outcome.

2.3. ELISA Assay {#sec2.3}
----------------

VEGF levels in samples were blindly assessed using a quantitative sandwich ELISA performed with the Human VEGF ELISA kit (Thermo Scientific) with a sensitivity of VEGF detection \>8 pg/mL. Briefly, VEGF levels were determined following capture with a solid phase monoclonal antibody to VEGF~165~ IgG and detected using a biotin-conjugated polyclonal rabbit antibody against recombinant human VEGF~165~. The assay was performed according to the manufacture\'s protocol and concentrations are reported as pg/mL. Data are presented as the results of two independent blinded ELISAs.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Results were derived from two independent blinded experiments and presented as the mean ±SEM with *P* \< 0.05 considered significant. Multiple group comparisons were made by one-way ANOVA. Two-way comparisons were performed by two-tailed, impaired Student\'s *t*-test. All analysis were performed using GraphPad Prism software version 5.0.3.

3. Results {#sec3}
==========

3.1. VEGF in Pulmonary Edema Fluid {#sec3.1}
----------------------------------

HPS patient pulmonary edema fluid (PEF) samples are rare since they were not routinely stored. However, twenty three serial samples of pulmonary edema fluid (PEF) were available from three HPS patients which we retrospectively analyzed for VEGF levels. *HPS Patient 1*: four PEF samples were taken on the first day of hospitalization at \~1 hour intervals from a patient with severe HPS, who died hours later. *HPS Patient 2*: six PEF samples were taken on the first day of hospitalization from a second patient with severe HPS, who survived after intubation and extracorporeal membrane oxygenation (ECMO). *HPS Patient 3*: thirteen PEF samples were taken on the first and second day after hospitalization from a third patient with moderate-mild HPS who survived after a brief intubation. We found the highest PEF VEGF levels (mean 625 ± 95 pg/mL) in the fatal HPS case ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#tab1){ref-type="table"}), and VEGF levels in patient 1 were approximately 4-fold higher than in the ECMO-treated HPS patient (140.8 pg/mL). Patient 1 VEGF levels were 10-fold higher than the VEGF levels of the HPS patient with moderate-mild disease (mean 60.0 pg/mL) or comparable patient control samples (52.4 pg/mL). The number of PEF samples collected from three patients is a sample limitation that does not allow extrapolating data to all HPS cases. However, PEF samples from three patients with different HPS manifestations suggest that elevated VEGF levels correlate with HPS severity.

3.2. Enhanced VEGF Levels in PBMCs {#sec3.2}
----------------------------------

We further studied PBMC-derived VEGF levels present in twenty-four HPS patient samples including: 24 with severe HPS, 2 moderate-severe cases, and 2 mild HPS patients. Mean VEGF levels in PBMCs from severe, moderate-severe, and mild HPS patient samples were 465.±85.7, 325 ± 075.0, and 105 ± 05.0 pg/mL, respectively. Differences in VEGF levels from severe and moderate cases versus control are statistically significant, *P* \< 0.001 and *P* \< 0.01, respectively, while VEGF levels in mild cases did not differ significantly from controls (*P* \> 0.05) ([Figure 2(a)](#fig2){ref-type="fig"}, [Table 1](#tab1){ref-type="table"}). PBMC VEGF levels were highest during the first 3 days of hospitalization (*n* = 16, mean 526 ± 108.5) compared to samples taken 4--17 days after admission (*n* = 11, mean 217 ± 39.6; *P* = 0.03) and were found to decrease over time ([Figure 2(b)](#fig2){ref-type="fig"}). This observation was confirmed by VEGF levels in paired samples of 6 HPS patients taken in the same intervals after hospitalization: 1--3 days (*n* = 6, mean 797.5 ± 200.2) versus 4--17 days (*n* = 6, mean 212.3 ± 36.9; *P* = 0.01) ([Figure 2(c)](#fig2){ref-type="fig"}).

3.3. VEGF Levels in Plasma and Sera {#sec3.3}
-----------------------------------

Serum VEGF levels were not statistically different between controls, mild, or severe HPS patient samples (3 severe and 4 mild cases) (*P* \> 0.05) ([Table 1](#tab1){ref-type="table"}). In contrast to PEF and PBMC samples, we found low-plasma VEGF levels in severe HPS cases during the first 3 days of hospitalization (*n* = 15, mean 30.4 ± 8.1), and an increase in plasma VEGF levels during recovery (*n* = 17, mean 212 ± 49.7; *P* = 0.001) (Figures [3(a)](#fig3){ref-type="fig"}, and [3(b)](#fig3){ref-type="fig"}; [Table 1](#tab1){ref-type="table"}). Plasma VEGF levels were, respectively, 2 to \>3 fold higher in mild and severe HPS patients than in controls. These results are consistent with localized rather than systemic permeability responses of VEGF and findings that released VEGF reportedly binds receptors within 0.5 mm of its release and is inactivated by circulating soluble receptors \[[@B36], [@B44]\].

3.4. VEGF Levels in Parallel Samples {#sec3.4}
------------------------------------

We blindly tested parallel samples, but after decoding noticed that a few samples that were taken from the same patients. In two cases, elevated VEGF levels were correspondingly observed in PEF and PBMC samples: severe HPS: 350 and 245 pg/mL, respectively moderate severe case 180 and 90 pg/mL; respectively. Additional positively correlated VEGF findings were detected in parallel PBMC and plasma samples from 7 patients (mean 229.2 ± 47.1 pg/mL and 79.3 ± 36.9 pg/mL; *P* = 0.03).

4. Discussion {#sec4}
=============

Pulmonary symptoms of HPS patients are characterized by hypoxia and extensive capillary leakage resulting in acute bilateral pulmonary edema \[[@B2], [@B5]--[@B7], [@B22], [@B42], [@B45]\]. Hypoxia induces pulmonary epithelial and endothelial cells to secrete VEGF \[[@B32], [@B34]--[@B37], [@B39], [@B40], [@B46], [@B47]\], and VEGF acts on the endothelium to stimulate growth and dissociate adherence junctions between endothelial cells \[[@B32], [@B36], [@B46], [@B48]--[@B51]\]. This permits vascular remodeling, vessel repair, and angiogenesis, but can also locally increase capillary permeability \[[@B32], [@B36], [@B39], [@B44], [@B46], [@B48], [@B49], [@B52]\]. A VEGF-HIF-1*α* amplification loop is responsible for high-altitude-induced pulmonary edema, and over expressing VEGF in the lung causes pulmonary edema \[[@B33]--[@B35], [@B37]--[@B40], [@B52], [@B53]\]. Conversely, genetic delivery of antiVEGF antibody or antagonizing VEGF responses suppresses pulmonary edema in experimental animals \[[@B37], [@B54]--[@B57]\].

ECMO reduces the progression of respiratory failure and the mortality of HPS from \~75% to 35--40% \[[@B2], [@B22], [@B58]\] suggesting a role for hypoxia-induced VEGF in HPS edema \[[@B34], [@B35], [@B39], [@B40], [@B47], [@B52], [@B59]\]. Pulmonary VEGF is associated with localized pathogenesis and as a cause of high-altitude pulmonary edema in response to reduced oxygen levels \[[@B6], [@B33], [@B33], [@B35]--[@B37], [@B39], [@B40], [@B47], [@B52]\]. Activated pulmonary PBMCs are increased in HPS patients and PBMCs also secrete VEGF in response to hypoxia suggesting a potential mechanism by which localized VEGF immune responses to hantavirus could contribute to disease \[[@B5]--[@B7], [@B60], [@B61]\]. Our findings indicate the presence of elevated VEGF in PEFs from severe and moderate HPS cases that are 4--10 fold above VEGF levels in patients with mild HPS and similar to PEF VEGF levels from patients with hydrostatic edema (median 799 pg/mL) or acute lung injury (median 501 pg/mL) \[[@B39], [@B40], [@B52], [@B62]\]. Our findings also indicate that HPS patient PBMCs contain high VEGF levels at acute stages 1--5 days after hospitalization, which diminished over time in paired patient samples (Figures [2(b)](#fig2){ref-type="fig"}, and [2(c)](#fig2){ref-type="fig"}). Although samples available were insufficient to analyze viremia here, these early VEGF responses occur with similar timing to the high-level viremia previously reported within HPS patients \[[@B63]\]. Collectively, these findings suggest that the reduced mortality observed following HPS patient oxygenation may be at least partly derived from inhibiting VEGF/HIF-1*α* responses which result in a concomitant reduction in hypoxia-directed pulmonary edema \[[@B34], [@B35], [@B37], [@B40], [@B47]\].

VEGF acts within millimeters of its release to prevent systemic capillary permeability \[[@B44]\], and serum VEGF is inactivated by binding to circulating soluble receptors \[[@B32], [@B36], [@B39], [@B52]\]. While localized PEF and PBMCs had high VEGF levels during acute HPS stages we found that circulating plasma and serum VEGF levels were low in severe HPS patients during acute HPS stages (1--5 days after hospitalization). In contrast, circulating serum and plasma VEGF levels only increased 11--20 days after-admission (Figures [3(a)](#fig3){ref-type="fig"}, and [3(b)](#fig3){ref-type="fig"}). Increased circulating VEGF at late times after infection is consistent with vascular remodeling and repair that occurs during recovery phases of other causes of acute pulmonary edema and may coincide with HPS convalescence \[[@B32], [@B33], [@B36], [@B39], [@B44], [@B46], [@B48], [@B49], [@B52], [@B64]\]. These findings are similar to studies of patients with high-altitude-induced pulmonary edema where pulmonary VEGF levels are associated with acute disease and plasma levels of VEGF only become elevated during recovery \[[@B33]\]. These findings suggest the direct involvement of localized PEF and PBMC VEGF responses in acute HPS pathogenesis and the potential for circulating VEGF to be a sign of patient recovery.

Hantaviruses infect endothelial cells in pulmonary capillary beds \[[@B2]\] and cause hypoxia in HPS patients \[[@B2], [@B5]--[@B7], [@B45]\]. Finding increased VEGF in PEFs and PBMCs from HPS cases suggests hypoxia-induced pulmonary VEGF induction as a potential edemagenic mechanism \[[@B33], [@B35], [@B39], [@B40], [@B46], [@B52]\]. This data is supported by *in vitro* results demonstrating that hantavirus-infected endothelial cells are hyperresponsive to the permeabilizing effects of VEGF and that blocking VEGFR2-Src signaling responses inhibits permeability \[[@B17], [@B18], [@B24], [@B30]\]. This mechanism is further linked to the ability of pathogenic hantaviruses to block *α* ~*v*~ *β* ~3~ integrin functions, which normally restrict VEGFR2 permeabilizing responses \[[@B18]--[@B21], [@B27], [@B28]\]. Thus HPS patient hypoxia in combination with hantavirus-infected VEGF-hyperresponsive endothelial cells is likely to contribute to acute pulmonary edema. Moreover, these results suggest that pathway specific VEGF inhibitors may be clinically relevant and used in tandem with ECMO to reduce the severity of HPS.
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![VEGF Levels in HPS Patient Pulmonary Edema Fluid. (a) Coded PEF samples from three patients were taken on the first and second days of hospitalization and tested by ELISA. Case 1 samples (*N* = 4) were taken at \~1 hour intervals from a patient presenting with severe HPS who died 6 hours after hospitalization. Case 2 samples (*N* = 6) were from a patient diagnosed with severe HPS who was intubated, ECMO-treated, and survived. Case 3 samples (*N* = 14) were from a patient with moderate HPS who was intubated and survived. Control VEGF levels are derived from 13 plasma samples from healthy individuals. Results from two independent ELISAs are presented and expressed as the mean SD. Differences between VEGF levels from the severe fatal patient were significantly different from those of severe ECMO-treated, moderate HPS or controls (*P* = 0.001) as determined by 1 way ANOVA test. VEGF levels of severe ECMO-treated patients were not significantly different from moderate HPS patients (*P* \> 0.05), however VEGF levels from severe ECMO-treated patients were significantly different from control (*P* = 0.01). (b) Individual PEF VEGF levels from patients are presented.](AV2012-674360.001){#fig1}

![PBMC VEGF Levels from HPS Patients. VEGF present in PBMC lysates was measured as in [Figure 1](#fig1){ref-type="fig"}. (a) Individual VEGF levels in PBMCs are presented. Samples from severe cases (*N* = 24), moderate (*N* = 2), mild (*N* = 2), and control (*N* = 6) were analyzed by 1 way ANOVA. VEGF levels in severe and moderate severe cases were not significantly different (*P* \> 0.05) (see [Table 1](#tab1){ref-type="table"}) and are presented as one group. PBMC VEGF levels were significantly different between severe/moderate and mild or control groups (*P* \< 0.001). (b) PBMC VEGF levels from patients with severe (20) HPS are presented (*P* \< 0.001) relative to their time of collection (samples collected 1--3 days or 4--17 days after admission). A two-tailed *t*-test shows significantly (*P* = 0.03) higher VEGF level at early days after hospitalization. (c) Paired patient PBMC samples from 6 patients with severe HPS were taken during the course of disease and analyzed for VEGF levels. VEGF levels from samples collected 1--3 days compared to 4--17 days after admission were significantly higher at early stages of disease (*P* = 0.01 using two-tailed *t*-test).](AV2012-674360.002){#fig2}

![Plasma VEGF Levels of HPS Patients. (a) Plasma VEGF levels were analyzed from patients with severe (*N* = 30) forms of HPS as in [Figure 1](#fig1){ref-type="fig"}. Group statistical analysis was made by comparing groups relative to their time of collection (1--5 days compared to 6--10, or 11--20 days) using one-way ANOVA. VEGF levels from samples taken 1--5 days after-admission (*N* 12; mean 86 ± 34.8 mg/mL) were significantly (*P* \< 0.05) lower than samples taken 11--20 days (*N* = 6; mean 262.2 ± 67.5 pg/mL) after-admission but not significant compared to samples taken 6--10 days or controls. Differences in plasma VEGF levels between severe and mild HPS patients were statistically insignificant (*P* \> 0.05). (b) Paired VEGF levels from 4 HPS patient plasma samples are presented.](AV2012-674360.003){#fig3}

###### 

VEGF level in HCPS patients samples.

  ------------------------------------------------------------------------------------
  \                  *n*   VEGF positive   VEGF pg/mL   *P* versus control   
  Sample                                                                     
  ------------------ ----- --------------- ------------ -------------------- ---------
  PEF                                                                         

   Severe lethal     4     4               340--730     625.0 ± 95.1         \<0.001

   Severe survival   6     6               105--180     140.8 ± 38.0         \<0.01

   Moderate severe   14    14              40--110      60.0 ± 5.1           \>0.05

   Control           13    13              20--80       52.4 ± 6.1            

  PBMC                                                                        

   Severe            24    23              \<8--1,480   465.0 ± 85.7         \<0.001

   Moderate          2     2               250--400     325.0 ± 75.0         \<0.01

   Mild              2     2               100--110     105.0 ± 5.0          \>0.05

   Control           6     6               10--150      61.5 ± 7.4            

  Plasma                                                                      

   Severe            39    30              10--527      174.4 ± 31.6         \<0.01

   Mild              17    8               10--310      94.2 ± 23.4          \>0.05

   Control           13    13              20--80       52.4 ± 6.1            

  Serum                                                                       

   Severe            3     3               50--60       51.3 ± 3.7           \>0.05

   Mild              4     2               \<8--110     32.5 ± 26.2          \>0.05

   Control           13    13              22--110      47.2 ± 17.5           
  ------------------------------------------------------------------------------------
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